• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BOD
Click for more information
0.00% 2.4¢

BOD SCIENCE LIMITED - Charts / Financials

Market Cap $4.256M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Bod Science Limited is an Australia-based cannabis focused drug development and product... Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for consumer and medical markets. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Company’s segments include medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 02/10/2024 (20 minute delay) ?
Day
Open 0.0¢   Day High 0.0¢   Day Low 0.0¢
Daily Volume 0
Bids   Sellers
Number Price Volume   Number Price Volume
0 0.0¢ 0   0 0.0¢ 0

Directors & Senior Management

Mr. Adrian Sturrock Chief Financial Officer
Mr. Craig Weller Chief Technical Officer
Ms. Carlie Hodges Company Secretary
Mr. David Baker Non-Executive Chairman of the Board
Mr. Akash Bedi Non-Executive Director
Dr. Hanno Cappon Non-Executive Director
Mr. George Livery Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
2.4¢ 		Change
0.000(0.00%) 		Mkt cap ! $4.256M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
SPC to merge with Original Juice Co and Nature One Dairy The Original Juice Co Ltd has set up a transaction which will see it merge with Aussie icon SPC Global and Singapore-based Nature One Dairy
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.